Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls

被引:3
|
作者
Galsky, Matthew D. [1 ]
Grewal, Simrun [2 ]
Liu, Yutong [3 ]
Fuldeore, Rupali [4 ]
Sesterhenn, Steve [4 ]
Chang, Nancy [2 ]
Hepp, Zsolt [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[2] Seagen Inc, Bothell, WA 98021 USA
[3] Genesis Res, Hoboken, NJ USA
[4] Astellas Pharma Inc, Northbrook, IL USA
关键词
Locally advanced or metastatic urothelial carcinoma; Opioid; Pain; Retrospective claims analysis; QUALITY-OF-LIFE; CANCER PAIN; MANAGEMENT; THERAPY; UPDATE; ACCESS; TRENDS;
D O I
10.1016/j.urolonc.2022.06.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Locally advanced or metastatic urothelial carcinoma (la/mUC) is an aggressive disease with a poor long-term survival. While patients frequently report pain, there are limited data on the patient experience with pain and pain medication use. This study used real-world data to quantify treatment with opioids, as a proxy for pain, in patients with la/mUC compared with matched non-cancer controls. Methods: This was a retrospective claims analysis, using the IBM (R) MarketScan (R) databases, of adults diagnosed with urothelial carcinoma and initiating >= 1 la/mUC therapy between May 2016 and June 2019. Index date was date of first systemic therapy claim for la/mUC; baseline was the 6 months pre-index; follow-up was from index until disenrollment or study end. Proportion with treatment with opioids, number of opioid prescriptions, and daily morphine-equivalent dose (MEQ; in morphine milligram equivalents/day) in patients with la/mUC and matched non-cancer controls from the same databases were assessed. Results: We identified 1293 patients with la/mUC and matched 1:3 with 3862 non-cancer controls. Mean (SD) follow-up was 1.26 (0.74) years in patients with la/mUC and 1.29 (0.72) years in controls. A greater proportion of patients with la/mUC, compared with controls, used opioids during both baseline (63.6% vs. 19.4%) and follow-up (61.4% vs. 27.9%). Among those who used opioids, mean monthly prescriptions (number of medica-tions claims/patient/month) were 0.55 both in patients with la/mUC and controls during baseline, and 0.49 and 0.39, respectively, at follow-up. Daily MEQ among those who used opioids was 53.6 and 45.7 during baseline, and 74.7 and 40.8 at follow-up, in patients with la/mUC and controls, respectively. In patients with la/mUC, mean opioid prescriptions and daily MEQ increased during later lines of therapy. Conclusion: In patients with la/mUC, pain requiring opioids is common at diagnosis, worsens as the patient progresses, and is consistently higher than in matched controls. Improvement in disease control with more effective therapies may reduce cancer pain in this population. (C) 2022 The Authors. Published by Elsevier Inc.
引用
收藏
页码:411.e9 / 411.e18
页数:10
相关论文
共 50 条
  • [1] Opioid use in locally advanced or metastatic urothelial carcinoma patients and matched non-cancer controls.
    Grewal, Simrun Kaur
    Hepp, Zsolt
    Liu, Yutong
    Fuldeore, Rupali
    Sesterhenn, Steve
    Chang, Nancy N.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma
    Omland, Lise H.
    Joensen, Ulla N.
    Toft, Birgitte G.
    Lund, Cecilia M.
    Lindberg, Henriette
    Knudsen, Mark B.
    Tolver, Anders
    Suetta, Charlotte
    Pappot, Helle
    ACTA ONCOLOGICA, 2022, 61 (09) : 1036 - 1042
  • [3] Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma
    Kopp, Ray Manneh
    Galanternik, Fernando
    Schutz, Fabio A.
    Kater, Fabio
    Ramos-Esquivel, Allan
    Neciosup, Silvia
    Sobrevilla-Moreno, Nora
    Vaca, Laura Bernal
    Ibata-Bernal, Linda
    Martinez-Rojas, Susan
    Bourlon, Maria T.
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [4] SYSTEMATIC LITERATURE REVIEW OF TREATMENT PATTERNS OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Hepp, Z.
    Shah, S. N.
    Vadagam, P.
    Smoyer, K.
    VALUE IN HEALTH, 2019, 22 : S94 - S94
  • [5] Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
    Loriot, Y.
    Necchi, A.
    Park, S. H.
    Garcia-Donas, J.
    Huddart, R.
    Burgess, E.
    Fleming, M.
    Rezazadeh, A.
    Mellado, B.
    Varlamov, S.
    Joshi, M.
    Duran, I.
    Tagawa, S. T.
    Zakharia, Y.
    Zhong, B.
    Stuyckens, K.
    Santiago-Walker, A.
    De Porre, P.
    O'Hagan, A.
    Avadhani, A.
    Siefker-Radtke, A. O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 338 - 348
  • [6] Erdafitinib for locally advanced or metastatic urothelial carcinoma
    Siefker-Radtke, Arlene O.
    Loriot, Yohann
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (11) : 824 - 825
  • [7] Avelumab in locally advanced or metastatic urothelial carcinoma
    Jackson-Spence, Francesca
    Szabados, Bernadett
    Toms, Charlotte
    Yang, Yu-Hsuen
    Sng, Christopher
    Powles, Thomas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (02) : 135 - 140
  • [8] Treatment with Opioids in Non-Cancer Pain
    Schiltenwolf, Marcus
    UNFALLCHIRURG, 2014, 117 (09): : 764 - 764
  • [9] Qualitative Analysis of Pain in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
    Martin, Susan
    Shah, Sonali N.
    Hepp, Zsolt
    Harris, Nimanee
    Morgans, Alicia K.
    BLADDER CANCER, 2022, 8 (01) : 45 - 53
  • [10] Maintenance therapy for locally advanced or metastatic urothelial carcinoma
    Rexer, H.
    Banek, S.
    Merseburger, A.
    UROLOGIE, 2024, 63 (02): : 208 - 209